Subject, grade 3 AST, alanine aminotransferase and lipase elevations, and mucositis grade 2 and 3 Other hours INDICATIVE side effects of treatment were diarrhea and hypopigmentation of the hair. The data lie S linear pharmacokinetics with a terminal half-life of 59,136 hours. Three patients with medull Ren thyroid carcinoma And a patient with neuroendocrine carcinoma had a PR, w While the IC-87114 DD in 20 patients, which lasted for more than 6 months for 12 of these patients was observed. Pharmacodynamic evaluation of plasma samples showed a tendency to gr Erer VEGF, placental growth factor and decreased L Soluble VEGFR-2 levels. Phase Ib / II trial of erlotinib with and without cabozantinib in patients with NSCLC Fifty Four patients with NSCLC with previously treated advanced NSCLC have again U cabozantinib and various combinations of erlotinib in 3T3 design.
Zw lf patients had at least one DLT Diarrhea, AST, palmar plantar Erythrodys Anesthesiology, mucositis, hypertension, Hypokali chemistry, hte increased lipase and fatigue. The h Ufigsten adverse events were grade 3/4 diarrhea, fatigue, shortness of breath and hypoxia. No drug interactions have been in the vorl Found ufigen pharmacokinetic CHIR-99021 GSK-3 inhibitor analysis. Three patients with previous erlotinib treatment phase, a reduction of at least 30% tumor measurements. One of these patients had amplification Rkung c MET. L SD was prolonged for at least 4 months in some patients Confinement usually choose patients with EGFR T790M mutation was observed.
Randomized phase II study of the judgment cabozantinib in advanced solid tumors, a phase II study the activity t of cabozantinib in patients with breast, gastric / gastroesophageal Sophagealen transition, the small cell, rated non-small cell lung, ovarian, pancreatic cancer, liver cancer and prostate cancer, melanoma or. The study consisted of two steps: a step to step in and do a double-blind, randomized study. For the market leader in the stadium, all patients were again U 100 mgof cabozantinib t Possible for 12 weeks. At the end of step 1, further patients with CR / PR to cancel the same dose of cabozantinib, patients with progressive disease, the treatment and these were received with SD were randomized 1:1 to cabozantinib get to step 2 until the progression of the disease. The placebo patients could cross over to progression cabozantinib.
Endpoints were response rate of 12 weeks in stage 1 and stage 2 PFS, with early stopping rules in the leading role in the stage at the futility of the project. Preferences INDICATIVE data from the top phase of the study for various tumor types. In the cohort of NSCLC, 36 patients were enrolled, whose disease is not responsive to a maximum of three prior systemic therapies, and 20 evaluable patients showed responses: two had a PR and eight SD and were randomized. The overall rate of disease control To 50% after 12 weeks and one patient with prior exposure to SUTENT a 61% decrease in tumor growth to 12 weeks weight Was carried. Another patient received prior platinum-based chemotherapy and EGFR inhibitors could, a 32% reduction in tumor size E Diarrhea, fatigue and pain in the extremities Th were the most hours Ufigsten observed events. Melanoma in the cohort of 24 evaluable patients showed responses: one patient with RA and 11 patients with SD. The overall rate controlled The disease rate wa